228 related articles for article (PubMed ID: 28932952)
1. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
[TBL] [Abstract][Full Text] [Related]
2. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
3. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma.
Marchioni M; Harmouch SS; Nazzani S; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Cancer Epidemiol; 2018 Jun; 54():112-118. PubMed ID: 29715680
[TBL] [Abstract][Full Text] [Related]
4. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Nazzani S; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Cancer Causes Control; 2020 Mar; 31(3):263-272. PubMed ID: 31993859
[TBL] [Abstract][Full Text] [Related]
5. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma.
Mazzone E; Nazzani S; Preisser F; Tian Z; Marchioni M; Bandini M; Capitanio U; Kapoor A; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; I Karakiewicz P
Cancer Epidemiol; 2018 Oct; 56():118-125. PubMed ID: 30173050
[TBL] [Abstract][Full Text] [Related]
6. Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Urol Oncol; 2022 Nov; 40(11):493.e9-493.e16. PubMed ID: 35907705
[TBL] [Abstract][Full Text] [Related]
7. Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Nimer N; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Dec; 40(12):2971-2978. PubMed ID: 36222885
[TBL] [Abstract][Full Text] [Related]
8. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.
Macleod LC; Tykodi SS; Holt SK; Wright JL; Lin DW; Tretiakova MS; True LD; Gore JL
Urology; 2015 Aug; 86(2):262-8. PubMed ID: 26199164
[TBL] [Abstract][Full Text] [Related]
9. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303
[TBL] [Abstract][Full Text] [Related]
10. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT
Marchioni M; Bandini M; Pompe RS; Martel T; Tian Z; Shariat SF; Kapoor A; Cindolo L; Briganti A; Schips L; Capitanio U; Karakiewicz PI
BJU Int; 2018 Mar; 121(3):383-392. PubMed ID: 28940649
[TBL] [Abstract][Full Text] [Related]
11. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
12. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Urol Oncol; 2020 May; 38(5):506-514. PubMed ID: 32139292
[TBL] [Abstract][Full Text] [Related]
13. First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany.
Cano Garcia C; Hoeh B; Mandal S; Banek S; Klümper N; Schmucker P; Hahn O; Mattigk A; Ellinger J; Cox A; Becker P; Zeuschner P; Zengerling F; Erdmann K; Buerk BT; Kalogirou C; Flegar L
Clin Genitourin Cancer; 2024 Aug; 22(4):102112. PubMed ID: 38825563
[TBL] [Abstract][Full Text] [Related]
14. Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study.
Eminaga O; Akbarov I; Wille S; Engelmann U
Int Urol Nephrol; 2015 Oct; 47(10):1653-63. PubMed ID: 26329746
[TBL] [Abstract][Full Text] [Related]
15. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma.
Trudeau V; Larcher A; Sun M; Boehm K; Dell'Oglio P; Sosa J; Tian Z; Fossati N; Briganti A; Shariat SF; Karakiewicz PI
World J Urol; 2016 Oct; 34(10):1429-36. PubMed ID: 26902877
[TBL] [Abstract][Full Text] [Related]
16. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
[TBL] [Abstract][Full Text] [Related]
17. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy.
Cano Garcia C; Flammia RS; Piccinelli M; Panunzio A; Tappero S; Barletta F; Incesu RB; Law KW; Morra S; Tian Z; Saad F; Kapoor A; Shariat SF; Longo N; Tilki D; Briganti A; Terrone C; Antonelli A; De Cobelli O; Hoeh B; Kluth LA; Chun FKH; Karakiewicz PI
Clin Genitourin Cancer; 2024 Feb; 22(1):1-6. PubMed ID: 37344282
[TBL] [Abstract][Full Text] [Related]
18. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis.
Sun M; Abdollah F; Bianchi M; Trinh QD; Jeldres C; Tian Z; Shariat SF; Widmer H; Zorn K; Menon M; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2011 Dec; 60(6):1152-9. PubMed ID: 21868147
[TBL] [Abstract][Full Text] [Related]
19. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
[TBL] [Abstract][Full Text] [Related]
20. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
